drugset
drugset / Trial / NCT04992377

R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL

NCT04992377 ↗

Phase 2 Unknown 30 enrolled Institute of Hematology & Blood Diseases Hospital, China Xian-Janssen Pharmaceutical Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an investigator-initiated Phase 2 study, which combines R-EDOCH with Ibrutinib to treat patients with Ritcher Transformation in consideration of DLBCL and CLL components both could being targeted at the same time. The investigator will observe the 2-year overall survival rate of this regimen for RT and explore the new regimen for RT in the novel drugs era, which aims to improve the efficacy and prolong survival.

Timeline

Start
2021-08-30
Primary completion
2024-08-30
Completion
2025-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibrutinib Small molecule 420 mg Oral
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 10 mg/m2 Intravenous
Background Etoposide Small molecule 50 mg/m2 Intravenous
Background Prednisone Other / unclassified 60 mg/m2 Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Vincristine Small molecule 0.4 mg/m2 Intravenous

Indications

Richter transformation